Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iScience Interventional, a developer of microcatheter platforms that enable specific treatment of ocular disease, has closed a series F financing round raising $20.5 million.
Subscribe to our email newsletter
Affinity Capital Management led the round with Johnson & Johnson Development, L Capital Partners, and Clarian Health Ventures participating as first time investors.
Existing investors, Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management also participated in the financing. Piper Jaffray & Company served as the placement agent for this transaction.
Michael Nash, president and CEO of iScience, said: “The treatment paradigms for many significant diseases of the eye such as glaucoma, age-related macular degeneration, and diabetic macular edema are in the midst of a revolutionary change. The need for access to the specific locations within the eye where these diseases occur is paramount to improving patient outcomes. The iTrack microcatheter uniquely provides such site-specific access, thus enabling an exciting new generation of medical therapies.”